Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
E2F-2
is a retinoblastoma (Rb)-regulated transcription factor induced during terminal erythroid maturation. Cyclin E-mediated Rb hyperphosphorylation induces E2F
transcriptional activator
functions. We previously reported that deregulated cyclin E activity causes defective terminal maturation of nucleated erythroblasts in vivo Here, we found that these defects are normalized by
E2F-2
deletion; however, anemia in mice with deregulated cyclin E is not improved by
E2F-2
-loss, which itself causes reduced peripheral red blood cell (RBC) counts without altering relative abundances of erythroblast subpopulations. To determine how
E2F-2
regulates RBC production, we comprehensively studied erythropoiesis using knockout mice and hematopoietic progenitors. We found that efficient stress erythropoiesis in vivo requires
E2F-2
, and we also identified an unappreciated role for
E2F-2
in erythroblast enucleation. In particular,
E2F-2
deletion impairs nuclear condensation, a morphological feature of maturing erythroblasts. Transcriptome profiling of
E2F-2
-null, mature erythroblasts demonstrated widespread changes in gene expression. Notably, we identified citron Rho-interacting kinase (CRIK), which has known functions in mitosis and cytokinesis, as induced in erythroblasts in an
E2F-2
-dependent manner, and we found that CRIK activity promotes efficient erythroblast enucleation and nuclear condensation. Together, our data reveal novel, lineage-specific functions for
E2F-2
and suggest that some mitotic kinases have specialized roles supporting enucleation of maturing erythroblasts.
...
PMID:E2F-2 Promotes Nuclear Condensation and Enucleation of Terminally Differentiated Erythroblasts. 2779 97